1 Widal F, Abrami P, Lermoyez J. First complete description of the aspirin idiosyncrasy-asthma-nasal polyposis syndrome (plus urticaria)--1922 (with a note on aspirin desensitization). J Asthma. 1987;24(5):297–300.
2 Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis. 1988;137(4):847–54.
3 Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Rubin P, Cohn J, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol. 1994;94(6Pt1):1046–56.
4 Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96.
5 Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diag-nosis, and management. J Allergy Clin Immunol. 2003;111(5):913–21.
6 Simon RA. NSAIDs (including aspirin): allergic and pseudoallergic reactions [Internet]. Teheran, Iran: UpToDate; 2022 (Abruf am 31.10.2022). Verfügbar unter:
https://medilib.ir/uptodate/show/2082
7 Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AI-ANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J. 2000;16(3):432–6.
8 Laidlaw TM, Israel E. Aspirin-exacerbated respiratory disease [Internet]. Alphen aan den Rijn, Niederlande: UpToDate; 2023 (Abruf am 31.10.2022). Verfügbar unter:
https://www.uptodate.com/contents/aspirin-exacerbated-respiratory-disease
9 Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin de-sensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Al-lergy Clin Immunol. 2003;111(1):180–6.
10 West PM, Fernández C. Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity. Ann Pharmacother. 2003;37(10):1497–501.